← Return to all swing-trade opportunities
TGTX — Trend Pullback to 20 EMA
Status: Invalidated
Scanner score: 65.0/100
Why this was flagged
TGTX was identified as a bullish technical setup based on the Trend Pullback to 20 EMA pattern. The scanner found a score of 65.0/100 using trend alignment, momentum, price action, volume, and risk-management rules. Monitor update: Latest daily-chart analysis no longer reports a bullish long setup.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
This computer tool looked at TG Therapeutics (TGTX) and gave it a score of 65 out of 100. It noticed a pattern called "Trend Pullback to 20 EMA." This means the stock price has been moving up, but it briefly dropped to a specific line traders watch. The scanner sees this as a rest before the price tries to go higher. It also checked that the stock’s price is above three key average lines, which usually shows strength. The momentum score, called RSI, is at 66. This number is healthy because it is not too high. If it were too high, the price might be overpriced.
What the price plan means
The plan says to look for a start price between $55.39 and $56.08. If the price drops to $51.27, the idea is considered wrong, and you would stop looking. This is your safety stop. The first goal for the price to reach is $63.63. The second goal is $67.76. The plan aims for a reward-to-risk ratio of 2. This means for every dollar you risk losing, the plan hopes to make two dollars. It is a math check to see if the potential gain is bigger than the possible loss.
What could make the idea fail
The current volume is only 73% of the usual amount. Low volume means fewer people are trading. This might make the price move slower or less. Also, the RSI is at 66. If it goes much higher, the stock might be too expensive, causing a pullback. The setup expires soon. If the price does not act correctly by then, this plan is no longer valid.
Important reminder
This is not financial advice. Do not buy or sell based on this text. Trading involves risk. Always check your own rules and ask a professional if you are unsure.
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Overall context: Positive (Moderate confidence)
TG Therapeutics is preparing to report second-quarter 2026 results, with Wall Street anticipating substantial growth in both earnings and revenue. Analysts expect earnings per share to increase by 141.2% to $0.41, alongside a 63.5% rise in revenue to $230.77 million. The stock currently trades at $55.39, aligning with a technical setup near the 20-day moving average. Management has also scheduled a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026, to discuss the company's pipeline, which includes its FDA-approved therapy, BRIUMVI, for multiple sclerosis.
Potentially supportive context
- Analysts project a 141.2% year-over-year increase in earnings per share to $0.41 for Q2 2026.
- Revenue is expected to grow by 63.5% to $230.77 million in the upcoming quarter.
- CEO Michael S. Weiss is scheduled to present at the Cantor Global Healthcare Conference on September 9, 2026.
Risks and caution items
- Investor sentiment remains dependent on the outcome of the Q2 2026 earnings report.
- As a biotechnology firm, the company is exposed to clinical trial risks and regulatory uncertainties.
Latest reviewed article: Sep 8, 2026 11:27 am
Recent related articles
TG Therapeutics (TGTX) is anticipated to report a significant year-over-year increase in earnings and higher revenues for the quarter ended June 2026. The company is expected to post earnings of $0.41 per share, a 141.2% increase, on revenues of $230.77 million, up…
TG Therapeutics, Inc. announced that its Chairman and CEO, Michael S. Weiss, will participate in the Cantor Global Healthcare Conference. He is scheduled to hold a fireside chat on September 9, 2026, at 11:30 AM ET. A live webcast of the event…
TG Therapeutics, Inc. (NASDAQ: TGTX) announced that its Chairman and CEO, Michael S. Weiss, will participate in a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026, at 11:30 AM ET. A live webcast of the event will be…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- Price is above the 20-, 50-, and 200-day moving averages, with bullish moving-average alignment.
- RSI is in a constructive momentum range without being overbought.
- Price is near the 20 EMA in a bullish trend and the current candle is positive.